Patents by Inventor Helena Freire Haddad

Helena Freire Haddad has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-polyethylene glycol (PEG) antibody mouse model for rigorous assessment of PEG-based therapies
    Patent number: 11890353
    Abstract: The present invention provides methods of making an in vivo animal model for detecting anti-poly(ethylene glycol) (PEG) antibodies. The methods of the disclosure comprises administering subcutaneously to an animal model a composition comprising antibodies against poly(ethylene glycol) chains with a molecular weight of at least 550 Da to maintain an anti-PEG antibody level within the animal model. The in vivo animal model can be used for testing and screening drugs and other compositions for adverse reactions, bioavailability, and immunogenicity prior to administration to a human subject.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: February 6, 2024
    Assignee: Northwestern University
    Inventors: Evan A. Scott, Guillermo A. Ameer, Jacqueline A. Burke, Helena Freire Haddad
  • ANTI-POLYETHYLENE GLYCOL (PEG) ANTIBODY MOUSE MODEL FOR RIGOROUS ASSESSMENT OF PEG-BASED THERAPIES: ADJUVANT-FREE INDUCTION MODEL
    Publication number: 20220119510
    Abstract: The present invention provides methods for generating a mouse model that produces anti-polyethylene glycol (PEG) antibodies. Also provided are mice generated by said methods and methods of using these mice to screen PEG-containing products in vivo.
    Type: Application
    Filed: October 15, 2021
    Publication date: April 21, 2022
    Inventors: Evan A. Scott, Guillermo A. Ameer, Helena Freire Haddad, Jacqueline A. Burke
  • Anti-Polyethylene Glycol (PEG) Antibody Mouse Model for Rigorous Assessment of PEG-Based Therapies
    Publication number: 20210106697
    Abstract: The present invention provides methods of making an in vivo animal model for detecting anti-poly(ethylene glycol) (PEG) antibodies. The methods of the disclosure comprises administering subcutaneously to an animal model a composition comprising antibodies against poly(ethylene glycol) chains with a molecular weight of at least 550 Da to maintain an anti-PEG antibody level within the animal model. The in vivo animal model can be used for testing and screening drugs and other compositions for adverse reactions, bioavailability, and immunogenicity prior to administration to a human subject.
    Type: Application
    Filed: October 15, 2020
    Publication date: April 15, 2021
    Applicant: NORTHWESTERN UNIVERSITY
    Inventors: Evan A. Scott, Guillermo A. Ameer, Jacqueline A. Burke, Helena Freire Haddad